Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
487 questions in 49 reviews · Breast Cancer
current versionsNo studies 44 · 9%Ungraded 14 · 2.9%Very low 108 · 22.2%Low 128 · 26.3%Moderate 107 · 22%High 86 · 17.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Systemic therapy vs control Change in stiffness from baseline to end of intervention · health problem or population Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early… (2022) · Cochrane | no estimate extracted | 4 studies · 295 participants | Very low |
Intervention NR General health‐related quality of life [assessed using a variety of scales, · women with primary breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | 8 studies · 1328 participants | Low |
Intervention NR Cancer‐specific quality of life [FACT‐G, FACT–B + ES, EORTC QLQ‐C30, · women with primary breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | 2009 | 2 studies · 557 participants | Moderate |
Intervention NR Anxiety and depression [HADS, STAI, · women with primary breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | RR 1.8 [0.4, 7.2] | 3 studies · 1094 participants | Moderate |
Intervention NR Service provision‐ patient perspective [ · women with primary breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | 4 studies · 1331 participants | Moderate |
Intervention NR General health‐related quality of life · women with advanced breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cancer‐specific quality of life [ · women with advanced breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | 1 study · 105 participants | Low |
Intervention NR Anxiety and depression · women with advanced breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Service provision (patient perspective) · women with advanced breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cancer‐specific quality of life [assessed using a variety of scales, · women with primary breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | 6 studies · 897 participants | Low |
Intervention NR Anxiety and depression [assessed using a variety of scales, · women with primary breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | 6 studies · 951 participants | Low |
Intervention NR Service provision‐patient perspective [ · women with primary breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | 2 studies · 320 participants | Low |
Intervention NR General health‐related quality of life [GHQ‐28, IES, · women with primary breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | 2 studies · 351 participants | Very low |
Intervention NR Cancer‐specific quality of life [EORTC QLQ‐C30, EORTC‐BR23, · women with primary breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | 1 study · 179 participants | Very low |
Intervention NR Anxiety and Depression [HADS, STAI, · women with primary breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | 2 studies · 351 participants | Very low |
Intervention NR Service provision‐patient perspective · women with primary breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR General health‐related quality of life [GHQ‐12, Mastery Scale, · women with primary breast cancer Specialist breast care nurses for support of women with breast cancer (2021) · Cochrane | no estimate extracted | 3 studies · 931 participants | Moderate |
Summary of Findings Table ‐ PBI?APBI vs WBRT Local recurrence‐free survival ‐ total (LR‐FS) · health problem or population Partial breast irradiation versus whole breast radiotherapy for early breast cancer (2021) · Cochrane | HR 1.21 [1.03, 1.42] | 8 studies · 13168 participants | Moderate |
Summary of Findings Table ‐ PBI?APBI vs WBRT Cosmesis, physician/nurse‐reported · health problem or population Partial breast irradiation versus whole breast radiotherapy for early breast cancer (2021) · Cochrane | OR 1.57 [1.31, 1.87] | 6 studies · 3652 participants | Moderate |
Summary of Findings Table ‐ PBI?APBI vs WBRT Overall survival · health problem or population Partial breast irradiation versus whole breast radiotherapy for early breast cancer (2021) · Cochrane | HR 0.99 [0.88, 1.12] | 8 studies · 13175 participants | High |
Summary of Findings Table ‐ PBI?APBI vs WBRT Subcutaneous fibrosis (late RT toxicity) · health problem or population Partial breast irradiation versus whole breast radiotherapy for early breast cancer (2021) · Cochrane | OR 5.07 [3.81, 6.74] | 2 studies · 3011 participants | Moderate |
Summary of Findings Table ‐ PBI?APBI vs WBRT Cause‐specific survival (C‐SS) · health problem or population Partial breast irradiation versus whole breast radiotherapy for early breast cancer (2021) · Cochrane | HR 1.06 [0.83, 1.36] | 7 studies · 9865 participants | Moderate |
Summary of Findings Table ‐ PBI?APBI vs WBRT Distant metastasis‐free survival (DM‐FS) · health problem or population Partial breast irradiation versus whole breast radiotherapy for early breast cancer (2021) · Cochrane | HR 0.95 [0.8, 1.13] | 7 studies · 11033 participants | Moderate |
Summary of Findings Table ‐ PBI?APBI vs WBRT Subsequent mastectomy · health problem or population Partial breast irradiation versus whole breast radiotherapy for early breast cancer (2021) · Cochrane | OR 0.98 [0.78, 1.23] | 3 studies · 3740 participants | High |
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine Overall survival (OS)median · people with metastatic breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | HR 1.01 [0.98, 1.05] | 12 studies · 4325 participants | High |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens pCR: hormone receptor‐positive · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | OR 1.22 [0.76, 1.95] | 4 studies · 964 participants | Moderate |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens pCR: hormone receptor‐negative · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | OR 1.28 [0.61, 2.66] | 4 studies · 646 participants | Moderate |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens Disease‐free survivalmedian · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | HR 1.02 [0.86, 1.21] | 4 studies · 2499 participants | High |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens Overall survivalmedian · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | HR 0.97 [0.77, 1.23] | 4 studies · 2499 participants | High |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens Febrile neutropenia · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | OR 1.31 [0.97, 1.77] | 4 studies · 2890 participants | Moderate |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens Diarrhoea · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | OR 1.95 [1.32, 2.89] | 3 studies · 2686 participants | Moderate |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens Hand‐foot syndrome · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | OR 6.77 [4.89, 9.38] | 5 studies · 3021 participants | Moderate |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy Disease‐free survival (DFS)median · people with early breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | HR 0.93 [0.86, 1.01] | 8 studies · 13547 participants | Moderate |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy DFS: hormone receptor‐positivemedian · people with early breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | HR 1.03 [0.91, 1.17] | 5 studies · 5604 participants | Moderate |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy DFS: hormone receptor‐negativemedian · people with early breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | HR 0.76 [0.65, 0.88] | 7 studies · 2879 participants | Moderate |
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine OS: hormone receptor‐positivemedian · people with metastatic breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | HR 0.9 [0.8, 1.02] | 6 studies · 1565 participants | High |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy Overall survival (OS)median · people with early breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | HR 0.89 [0.81, 0.98] | 8 studies · 13547 participants | Moderate |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy Febrile neutropenia · people with early breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | OR 0.55 [0.47, 0.64] | 5 studies · 8086 participants | Moderate |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy Diarrhoea · people with early breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | OR 2.46 [2.01, 3.01] | 8 studies · 11207 participants | Moderate |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy Hand‐foot syndrome · people with early breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | OR 13.6 [10.65, 17.37] | 8 studies · 11207 participants | Moderate |
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine OS: hormone receptor‐negativemedian · people with metastatic breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | HR 1.05 [0.91, 1.2] | 7 studies · 1408 participants | High |
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine Progression‐free survival (PFS)median · people with metastatic breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | HR 0.89 [0.83, 0.96] | 12 studies · 4325 participants | Moderate |
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine PFS: hormone receptor‐positivemedian · people with metastatic breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | HR 0.77 [0.68, 0.87] | 6 studies · 1372 participants | Moderate |
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine PFS: hormone receptor‐negativemedian · people with metastatic breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | HR 1.01 [0.85, 1.19] | 6 studies · 900 participants | Moderate |
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine Objective response rate · people with metastatic breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | RR 0.97 [0.84, 1.11] | 12 studies · 4200 participants | Moderate |
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine Quality of life · people with metastatic breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | no estimate extracted | 5 studies · 5 participants | Low |
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens Pathological complete response (pCR): breast and axillary nodes · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer (2021) · Cochrane | OR 1.12 [0.94, 1.33] | 6 studies · 3152 participants | High |
PARPi‐containing regimen vs non‐PARPi regimen Overall Survival** · locally advanced or metastatic breast cancer PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer (2021) · Cochrane | HR 0.84 [0.76, 1] | 4 studies · 1435 participants | High |
PARPi‐containing regimen vs non‐PARPi regimen Progression Free Survival** · locally advanced or metastatic breast cancer PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer (2021) · Cochrane | HR 0.63 [0.56, 0.71] | 5 studies · 1474 participants | High |
PARPi‐containing regimen vs non‐PARPi regimen Response Rate · locally advanced or metastatic breast cancer PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer (2021) · Cochrane | RR 1.39 [1.24, 1.54] | 5 studies · 1185 participants | Low |